SCHEMBL20203893

SCHEMBL20203893

Cc1nc(OCC(F)(F)F)ccc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
MBOAT4 Q96T53 3/20 0.39
DGAT1 O75907 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
AMD1 P17707 1/20 0.33
NUDT1 P36639 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
HPGDS O60760 1/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAPT P10636 1/20 0.32
CYP17A1 P05093 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19962935 0.84 DGAT1 (0.36) L3MBTL1MBOAT4DGAT1SMN1; SMN2NUDT1
SCHEMBL23414825 0.81 L3MBTL1 (0.45) L3MBTL1SMN1; SMN2HPGDSPOLBMAPK1
SCHEMBL20203884 0.80 L3MBTL1 (0.39) L3MBTL1MBOAT4SMN1; SMN2NUDT1MEN1
SCHEMBL19962931 0.79 NUDT1 (0.49) DGAT1SMN1; SMN2NUDT1LMNAKMT2A
SCHEMBL16783076 0.78 BTK (0.37) L3MBTL1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL27913769 0.78 L3MBTL1 (0.40) L3MBTL1DGAT1SMN1; SMN2MEN1LMNA
SCHEMBL2713247 0.77 L3MBTL1 (0.42) L3MBTL1DGAT1SMN1; SMN2MEN1KMT2A
SCHEMBL2713423 0.77 L3MBTL1 (0.39) L3MBTL1DGAT1SMN1; SMN2NUDT1MEN1
SCHEMBL4550309 0.77 L3MBTL1 (0.39) L3MBTL1DGAT1SMN1; SMN2NUDT1MEN1
SCHEMBL2714878 0.76 MBOAT4 (0.40) MBOAT4SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 US disclosed
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 US disclosed
WO-2018098499-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B L3MBTL1 1392/4885MBOAT4 2260/4885DGAT1 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.